Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis

Nov 2 (Reuters) - Pfizer raised its annual profit and revenue forecasts on Tuesday, banking on strong demand for its blood thinner Eliquis.

The U.S. drugmaker expects annual sales of $62 billion to $64.0 billion, up from $60.5 billion to $62.5 billion forecast previously. It expects to earn adjusted per-share of $2.95 to $3.05 this year, compared with previous forecast of $2.80 to $3.00 per share.

Analysts’ on average were expecting annual per-share profit of $2.96 and 2026 revenue of $62.17 billion.